MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction (MIBRAIN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01803984 |
Recruitment Status
: Unknown
Verified January 2015 by University Hospital, Bordeaux.
Recruitment status was: Recruiting
First Posted
: March 4, 2013
Last Update Posted
: January 14, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Migraine is a very common, chronic/intermittent and disabling neurovascular headache disorder that has long believed to have no severe consequences. Recent evidence, however, strongly suggest that migraine is associated with increased risk of ischemic stroke and there is initial evidence that migraine is associated with structural brain changes independent of the occurrence of stroke.
As migraine has strong links with the vascular system, it is plausible that vascular functions interact on the association between migraine and structural brain changes as well as cognition.
Our primary objectives are to investigate: (i) the relationship of migraine and migraine subtypes on magnetic resonance imaging (MRI) changes in a cohort of patients with active migraine; (ii) the relationship of migraine on cognitive performance among patients with active migraine; and (iii) the relationship of migraine and migraine specifics with vascular functions and morbidity. As secondary objective, we investigate whether the association of migraine on structural brain changes or cognitive performance is modified by vascular functions.
This will be an observational study conducted in the Headache Center in Bordeaux. 300 patients have to be included (150 patients with migraine with aura and 150 patients with migraine without aura).
Inclusion criteria are: all patients with a clearly defined migraine (as per IHS[International Headache Classification] criteria) who are aged 30 and older, are able to fluently speak French, and who are willing to participate.
Exclusion criteria are: pregnant woman and patient who have a major psychiatric disease or major anxiety disorder or had a pacemaker (which would not allow to perform a MRI imaging).
The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). In addition to the RBANS, we will use the HIT-6 (Headache Impact Test) and MIDAS (MIgraine Disability ASessment) and the depression scale CES-D (Center for Epidemiologic Studies Depression Scale).
Vascular risk status will be assessed by measurement of blood pressure and reports of vascular risk factors. The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device (Itamar Medical Inc, Framingham, MA).
For crude comparisons, chi-square tests will be used for categorical variables and t-test for continuous variables. Multivariable-multinominal modeling techniques will be utilized for the comparisons adjusting for potential confounding variables. All statistical tests will be two-tailed and a P <0.05 will be considered statistically significant.
Condition or disease | Intervention/treatment |
---|---|
Migraine | Device: MRI Device: EndoPAT Other: Neuropsychological battery |
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction |
Study Start Date : | March 2013 |
Estimated Primary Completion Date : | June 2015 |
Estimated Study Completion Date : | June 2015 |

Group/Cohort | Intervention/treatment |
---|---|
Patient with migraine with aura
Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
|
Device: MRI
Device: EndoPAT
The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
Other: Neuropsychological battery
The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
|
Patient with migraine without aura
patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
|
Device: MRI
Device: EndoPAT
The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
Other: Neuropsychological battery
The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
|
- Differences in magnetic resonance imaging (MRI) between migraine without aura and migraine with aura patients (frequency of hyperintensities, white matter lesions....) [ Time Frame: Within 3 months after inclusion ]
- Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between migraine without aura and migraine with aura patients. [ Time Frame: Baseline ]The Total Score of the RBANS reflects the neurocognitive status of the patient by summing five index/domain scores. The domains are Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory.
- Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between migraine without aura and migraine with aura patients [ Time Frame: Baseline ]RHI will measured by the non invasive endothelial peripheral arterial tomography (EndoPat 2000 Itamar Medical Ltd) device.
- Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between migraine groups. [ Time Frame: Within 3 months after inclusion ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient with migraine according to the criteria defined by the International Headache Society (ICHD-II)
- Patient aged 30 years old and older
- Patient speaking fluent french
Exclusion Criteria:
- pregnant woman
- patient with a serious psychiatric psychological illness
- patient having a serious anxiety (claustrophobia)
- Patient bearing an electronic or a metallic device (pacemaker)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01803984
Contact: Tobias Kurth, MD | +33 5 47 30 42 56 | tobias.kurth@univ-bordeaux.fr |
France | |
Centre Hospitalier Universitaire de Bordeaux | Recruiting |
Bordeaux, France, 33000 | |
Contact: Tobias KURTH, MD +33 5 47 30 42 56 tobias.kurth@univ-bordeaux.fr | |
Principal Investigator: Virginie DOUSSET, MD |
Principal Investigator: | Tobias KURTH, MD | Inserm Unit 708 - Neuroépidemiologie |
Responsible Party: | University Hospital, Bordeaux |
ClinicalTrials.gov Identifier: | NCT01803984 History of Changes |
Other Study ID Numbers: |
CHUBX 2012/19 |
First Posted: | March 4, 2013 Key Record Dates |
Last Update Posted: | January 14, 2015 |
Last Verified: | January 2015 |
Keywords provided by University Hospital, Bordeaux:
Migraine Brain structure MRI |
Additional relevant MeSH terms:
Migraine Disorders Headache Disorders, Primary Headache Disorders |
Brain Diseases Central Nervous System Diseases Nervous System Diseases |